HDAC9 and cancer: In recent years, two major classes of epigenetic drugs, histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, have demonstrated significant potential as immunomodulatory agents in diseases such as cancer [67–69].